These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
386 related articles for article (PubMed ID: 35936736)
41. Cross-talk between necroptosis-related lncRNAs to construct a novel signature and predict the immune landscape of lung adenocarcinoma patients. Wu J; Song D; Zhao G; Chen S; Ren H; Zhang B Front Genet; 2022; 13():966896. PubMed ID: 36186456 [No Abstract] [Full Text] [Related]
42. A novel cuproptosis-related lncRNA nomogram to improve the prognosis prediction of gastric cancer. Feng A; He L; Chen T; Xu M Front Oncol; 2022; 12():957966. PubMed ID: 36106123 [TBL] [Abstract][Full Text] [Related]
43. Identification of a cuproptosis-related lncRNA prognostic signature in lung adenocarcinoma. Chen R; Luo H; Chen Q; Wang C Clin Transl Oncol; 2023 Jun; 25(6):1617-1628. PubMed ID: 36609650 [TBL] [Abstract][Full Text] [Related]
44. Prognostic Value of Genomic Instability of m Li R; Li JP; Liu TT; Huo C; Yao J; Ji XL; Qu YQ Front Cell Dev Biol; 2022; 10():707405. PubMed ID: 35309906 [No Abstract] [Full Text] [Related]
45. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma. Chen Y Front Genet; 2022; 13():912037. PubMed ID: 35937995 [No Abstract] [Full Text] [Related]
46. A Newly Established Cuproptosis-Associated Long Non-Coding RNA Signature for Predicting Prognosis and Indicating Immune Microenvironment Features in Soft Tissue Sarcoma. Han J; Hu Y; Liu S; Jiang J; Wang H J Oncol; 2022; 2022():8489387. PubMed ID: 35847354 [TBL] [Abstract][Full Text] [Related]
47. A risk model based on ferroptosis- and cuproptosis-related lncRNAs predicts prognosis and immune microenvironment in lung adenocarcinoma by bioinformatics analysis and experimental verification. Xu X; Feng X; Zhang P; Lin X Am J Cancer Res; 2023; 13(11):5306-5319. PubMed ID: 38058804 [TBL] [Abstract][Full Text] [Related]
48. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma. Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203 [TBL] [Abstract][Full Text] [Related]
49. Clinical significance and immune landscape of cuproptosis-related lncRNAs in kidney renal clear cell carcinoma: a bioinformatical analysis. Li D; Wu X; Song W; Cheng C; Hao L; Zhang W Ann Transl Med; 2022 Nov; 10(22):1235. PubMed ID: 36544675 [TBL] [Abstract][Full Text] [Related]
50. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature. Sui J; Yang S; Liu T; Wu W; Xu S; Yin L; Pu Y; Zhang X; Zhang Y; Shen B; Liang G J Cell Biochem; 2019 Jan; 120(1):705-714. PubMed ID: 30125988 [TBL] [Abstract][Full Text] [Related]
51. LncRNA SGMS1-AS1 regulates lung adenocarcinoma cell proliferation, migration, invasion, and EMT progression via miR-106a-5p/MYLI9 axis. Liu T; Yang C; Wang W; Liu C Thorac Cancer; 2021 Jul; 12(14):2104-2112. PubMed ID: 34061466 [TBL] [Abstract][Full Text] [Related]
52. Comprehensive analysis of the prognostic signature and tumor microenvironment infiltration characteristics of cuproptosis-related lncRNAs for patients with colon adenocarcinoma. Cui G; Liu J; Wang C; Gu R; Wang M; Sun Z; Wei F Front Oncol; 2022; 12():1007918. PubMed ID: 36212459 [TBL] [Abstract][Full Text] [Related]
53. Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma. Yang D; He Y; Wu B; Liu R; Wang N; Wang T; Luo Y; Li Y; Liu Y Cancer Biomark; 2020; 29(3):399-416. PubMed ID: 32741804 [TBL] [Abstract][Full Text] [Related]
54. A novel prognostic signature based on cuproptosis-related lncRNA mining in colorectal cancer. Hou D; Tan JN; Zhou SN; Yang X; Zhang ZH; Zhong GY; Zhong L; Yang B; Han FH Front Genet; 2022; 13():969845. PubMed ID: 36105091 [No Abstract] [Full Text] [Related]
55. Identification of ceRNA network based on a RNA-seq shows prognostic lncRNA biomarkers in human lung adenocarcinoma. Li X; Li B; Ran P; Wang L Oncol Lett; 2018 Nov; 16(5):5697-5708. PubMed ID: 30344725 [TBL] [Abstract][Full Text] [Related]
56. Identification and verification of a prognostic ferroptosis-related lncRNAs signature for patients with lung adenocarcinoma. Qi K; Liu XL; Chen XL; Song C; Peng JH; Xu JJ Am J Transl Res; 2022; 14(6):3698-3715. PubMed ID: 35836852 [TBL] [Abstract][Full Text] [Related]
57. Identification and validation of a novel cuproptosis-related lncRNA signature for prognosis and immunotherapy of head and neck squamous cell carcinoma. Xu QS; Shen ZZ; Yuan LQ Front Cell Dev Biol; 2022; 10():968590. PubMed ID: 36467424 [TBL] [Abstract][Full Text] [Related]
58. Identification of cuproptosis-related long non-coding ribonucleic acid signature as a novel prognosis model for colon cancer. Xu R; Wu X; Du A; Zhao Q; Huang H Am J Cancer Res; 2022; 12(11):5241-5254. PubMed ID: 36504883 [TBL] [Abstract][Full Text] [Related]
59. Identification of a novel prognosis-associated ceRNA network in lung adenocarcinoma via bioinformatics analysis. Li Y; Yu X; Zhang Y; Wang X; Zhao L; Liu D; Zhao G; Gao X; Fu J; Zang A; Jia Y Biomed Eng Online; 2021 Nov; 20(1):117. PubMed ID: 34819106 [TBL] [Abstract][Full Text] [Related]
60. Construction of a cuproptosis-associated lncRNA prognostic signature for bladder cancer and experimental validation of cuproptosis-related lncRNA UBE2Q1-AS1. Shen J; Du M; Liang S; Wang L; Bi J Front Med (Lausanne); 2023; 10():1222543. PubMed ID: 37614950 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]